Strand V - Search Results

1

Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.

Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M; OMERACT-OARSI. Pham T, et al. Among authors: strand v. J Rheumatol. 2003 Jul;30(7):1648-54. J Rheumatol. 2003. PMID: 12858473 Review.

2

OMERACT II: the biologics perspective.

Strand V. Strand V. J Rheumatol. 1995 Jul;22(7):1415-7. J Rheumatol. 1995. PMID: 7562788 Review.

3

Health status instruments / utilities.

Bellamy N, Boers M, Felson D, Fries J, Furst D, Henry D, Liang M, Lovell D, March L, Strand V, et al. Bellamy N, et al. Among authors: strand v. J Rheumatol. 1995 Jun;22(6):1203-7. J Rheumatol. 1995. PMID: 7674258

4

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. Felson DT, et al. Among authors: strand v. Arthritis Rheum. 1995 Jun;38(6):727-35. doi: 10.1002/art.1780380602. Arthritis Rheum. 1995. PMID: 7779114

5

OMERACT and the clinical evaluation of new therapeutic agents: a bird's eye view. OMERACT Committee.

Strand V. Strand V. J Rheumatol. 1993 Mar;20(3):588-9. J Rheumatol. 1993. PMID: 8478881 Review. No abstract available.

6

Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III.

Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M. Bellamy N, et al. Among authors: strand v. J Rheumatol. 1997 Apr;24(4):799-802. J Rheumatol. 1997. PMID: 9101522 Review.

7

Clinical response to nonsteroidal antiinflammatory drugs.

Simon LS, Strand V. Simon LS, et al. Among authors: strand v. Arthritis Rheum. 1997 Nov;40(11):1940-3. doi: 10.1002/art.1780401104. Arthritis Rheum. 1997. PMID: 9365081 No abstract available.

8

Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology.

Gazarian M, Tugwell P, Boers M, Bombardier C, Brooks P, Day R, Strand V, Wells G. Gazarian M, et al. Among authors: strand v. J Rheumatol. 1999 Jan;26(1):207-9. J Rheumatol. 1999. PMID: 9918265

9

Outcome measures to be used in clinical trials in systemic lupus erythematosus.

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Strand V, et al. J Rheumatol. 1999 Feb;26(2):490-7. J Rheumatol. 1999. PMID: 9972993

10

Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains.

Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, Gordon C, Isenberg DA, Klippel JH, Petri M, Simon L, Tugwell P, Wolfe F. Smolen JS, et al. Among authors: strand v. J Rheumatol. 1999 Feb;26(2):504-7. J Rheumatol. 1999. PMID: 9972996

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

534 results

Search Page

Filters